Massachusetts General Hospital

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,742 sponsors by registered trial count).

2,032 total trials 336 currently recruiting 1284 completed early-phase tilt top decile by trial count

Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.

Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.

Top-decile sponsor footprint

Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 55/100

1,284 of 1,487 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

2,032 total, page 31 of 41

TERMINATED NA

Does Percutaneous Tibial Nerve Stimulation (PTNS) Improve Outcomes in Patients Presenting With Fecal Incontinence

NCT01274585
COMPLETED NA

Could Meditation Modulate the Neurobiology of Learning Not to Fear?

NCT01320969
COMPLETED Phase 1

Study to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Elderly Subjects

NCT01274598
COMPLETED NA

DAYLIGHT: Vitamin D Therapy in Individuals at High Risk of Hypertension

NCT01240512
COMPLETED NA

Effects of Growth Hormone Releasing Hormone in HIV

NCT01263717
COMPLETED Phase 2

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

NCT01239394
COMPLETED NA

A Novel Approach to Methicillin-resistant Staphylococcus Aureus (MRSA) Screening of Colonized Patients

NCT01234831
TERMINATED Phase 4

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

NCT01260649
COMPLETED NA

Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)

NCT01325532
COMPLETED Phase 4

Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders

NCT01631682
TERMINATED Phase 4

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

NCT01246011
COMPLETED NA

Individualized Stereotactic Body Radiotherapy of Liver Metastases

NCT01239381
COMPLETED NA

In-Room PET in Proton Radiation Therapy

NCT01228448
COMPLETED NA

Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus

NCT01439633
COMPLETED

Perception Prognosis, Goals of Treatment, and Communication

NCT01401894
COMPLETED NA

Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents

NCT01287208
TERMINATED Phase 2

IPI-504 in NSCLC Patients With ALK Translocations

NCT01228435
COMPLETED Phase 1

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

NCT01078961
COMPLETED Phase 4

Comparative Effectiveness Study for Bipolar Disorder

NCT01331304
COMPLETED NA

Vitamin D Deficiency in Adolescent Girls

NCT01180946
COMPLETED Phase 4

A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients

NCT01201967
TERMINATED Phase 2

Metformin in Castration-Resistant Prostate Cancer

NCT01215032
TERMINATED NA

Neuroimaging for Depression

NCT00864630
TERMINATED

Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer

NCT01226888
COMPLETED Phase 1

STA-9090 in Patients With Advanced Hepatocellular Cancer

NCT01665937
COMPLETED Phase 3

Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

NCT01302964
COMPLETED Phase 1

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

NCT01188876
COMPLETED Phase 2

Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention

NCT01188967
COMPLETED Phase 2

Tandem Auto-Allo Transplant for Lymphoma

NCT01181271
COMPLETED NA

Effectiveness of a Relaxation-Response Based Cognitive Behavioral Therapy Group for Depressed Chinese Patients

NCT01359839
COMPLETED Phase 2

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

NCT01167114
TERMINATED

Comparison of Xtreme CT and DXA Bone Densitometry

NCT01199991
COMPLETED NA

Impact of Vitamin D Supplementation on Cardiac Structure and Function

NCT01630213
COMPLETED NA

Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling

NCT01684943
COMPLETED NA

Effects of Blood Transfusion in Healthy Volunteers

NCT01226498
COMPLETED NA

Smoking Interventions for Hospital Patients

NCT01177176
COMPLETED NA

Emotion Regulation Group Therapy for Bipolar Disorder

NCT01207505
COMPLETED NA

Using Videos to Improve Understanding of the Delivery of End-of-life Medical Care in Non-hospital Settings

NCT01233973
TERMINATED Phase 2

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

NCT01173679
COMPLETED

Metabolic and Psychological Changes Associated With Menopause Among Women With HIV

NCT01142817
COMPLETED Phase 4

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

NCT01082588
COMPLETED Phase 4

Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots

NCT01149876
COMPLETED Phase 2

High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma

NCT01182415
COMPLETED

Effect of Spinal Cord Stimulation on Pain Thresholds and Sensory Perception in Chronic Pain Patients.

NCT01137617
TERMINATED NA

Ultrasound Method to Measure Fibrosis of the Liver in Children

NCT02086708
TERMINATED

Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders

NCT01165619
COMPLETED NA

Stress Reduction and Anxiety: Effects on the Function and Structure of the Brain

NCT01128309
COMPLETED Phase 2

Pilot Study of Open-label Placebo to Treat Major Depressive Disorder

NCT01103271
COMPLETED NA

Computer Assisted Planing of Corrective Osteotomy for Distal Radius Malunion

NCT01193010
TERMINATED Phase 2

Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women

NCT01126801
← Previous Page 31 of 41 Next →

Phase Distribution

PhaseTrial count
Phase 1 226
Phase 2 289
Phase 3 58
Phase 4 182

Therapeutic Areas

Depression 29
Major Depressive Disorder 19
Breast Cancer 16
Lung Cancer 15
Multiple Myeloma 14
Obesity 13
Healthy 12
Cancer 12
Schizophrenia 11
Bipolar Disorder 11

What is open in the Massachusetts General Hospital pipeline

336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).

Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).

Top condition: Depression (29 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Massachusetts General Hospital: open-pipeline peers nationwide

Peers matched on 2,032 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Massachusetts General Hospital sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,0002,500 5%10%15%20% Total trials Recruiting share Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID)Memorial Sloan Kettering Cancer CenterPfizerStanford UniversityRush University Medical CenterOHSU Knight Cancer InstituteAdageneAgendia
Massachusetts General Hospital sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Massachusetts General Hospital sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2,032 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Massachusetts General Hospital page

2,032 registered trials is a research-attention snapshot, not an endorsement of Massachusetts General Hospital or any single study.

  • 336 of Massachusetts General Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Massachusetts General Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Massachusetts General Hospital pipeline card: 2,032 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.